Radioiodine whole body imaging

Thyroid Cancer (Second Edition): A Comprehensive Guide to Clinical Management

Volumn , Issue , 2006, Pages 133-150

  Atkins, Frank B ^a   Van Nostrand, Douglas ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34547217045     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-995-0_14     Document Type: Chapter

References (37)

1. Procedure Guideline for Extended Scintigraphy for Differentiated Thyroid Cancer. Society of Nuclear Medicine, 2003; 19-23.
2. Schlumberger M, Tubiana M, De Vathaire F, et al. Long term results of treatment of 283 patients with lung bone and metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 63:960-967.
3. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987; 28: 1888-1891.
4. Cailleux AF, Baudin E, Travagli J P, Schlumberger RM. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000; 85:175-178.
5. Wartofsky L. Clinical utility of rh-TSH-stimulated thyroglobulin testing without scan in the follow-up of differentiated thyroid cancer. Denver, Co: Program of the 83rd Annual Meeting of the Endocrine Society; 2000:P2-P535.
6. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002; 87: 1490-1498.
7. Wartofsky L. Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid cancer without diagnostic I-131 scanning. J Clin Endocrinol Metab 2002; 87:1486-1489.
8. Maxon HR, Smith HR. Radioiodine-131 in the diagnosis and treatment of metastatic well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19:685-718.
9. Mandel SJ, Shankar LK, Benard F, et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nuc Med 2001; 26:6-9.
10. Jeevanram RK, Shah DH, Shama M, et al. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patient. Nucl Med Biol 1986; 13:277.
11. 131I sodium iodide total body scanning in thyroid cancer patients. J Nucl Med 1996; 37:251P.
12. Berbano B, Naddaf S, Echemendia, et al. Use of iodine-123 as a diagnostic tracer for neck and whole body scanning in patients with well-differentiated thyroid cancer. Endocrine Practice 1998; 4:11-16.
13. 123I for the diagnostic evaluations of patients with thyroid cancer. J Nucl Med 1993; 34:42P.
14. Yaakob W, Gordon L, Spicer KM, Nitke SJ. The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metas-tases. J Nucl Med Tech 1999; 27:279-281.
15. 123I Scintigraphy in the management of differentiated thyroid cancer. J Nucl Med 2002; 43:526.
16. Shankar LK, Yamamoto AJ, Alavi A, et al. Comparison of I-123 scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med 2002; 43:72-76.
17. 123I diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nuc Med 2002; 27:1-8.
18. 131I therapy whole body scanning. J Clin Endocrinol Metab 2001; 86:5294-5300.
19. 131I scanning; avoidance of negative therapeutic uptake due to stunning. Clin Endocrinol 2001; 55: 515-521.
20. 131I for whole body imaging in thyroid cancer. J Nucl Med 2002; 43: 632-634.
21. 131I in thyroid remnant following s urgery for differentiated thyroid cancer. J Nucl Med 2002; 43:129P.
22. 131I for whole body imaging after stimulation by recombinant human thy-rotropin: a preliminary report. Clin Nuc Med 2003; 28:93-96.
23. Eschmann, SM, Reischl G, Bilger K, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. E uro J Nuclear Med 2002; 29: 760-767.
24. Sgouros G, Kolbert KS, Sheikh A, et al. Patient-specific dosimetry for I-131 thyroid cancer therapy using I-124 PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004; 45: 1366-1372.
25. Nemec J, Rohling S, Zamarazil V, Pohunkova D. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 1997; 20:92-97.
26. Balachandran S, Sayle BA. V a l ue of thyroid carcinoma imaging after therapeutic doses of radioiodine. Clin Nucl Med 1981; 6:162-167.
27. Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of post treatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994; 78:629-634.
28. Spies WG, Wojtowicz CH, Spies SM, et al. V a l ue of post-therapy whole-body I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose I-131 therapy. Clin Nucl Med 1989; 14:793-800.
29. Fatourechi V, Hay ID, Mullan BP, et al. Are post therapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 2000; 10:573-577.
30. Pineda JD, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Meta 1995; 80:1488-1492.
31. Rosario PWSD, Barroso AL, Rezende LL, et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases; an unnecessary cost or a relevant contribution? Clin Nuc Med 2004; 29:795-798.
32. Dorn R, Kopp J, Vogt H, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nuc Med 2003; 44:451-456.
33. Thomas SR, Maxon HR, Kereiakes JG, Saenger EL. Quantitative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well differentiated thyroid cancer. Radiology 1997; 122:731-737.
34. Comtois R, Theriault C, Del Vecchio P. Assessment of the efficacy of iodine-131 for thyroid ablation. J Nucl Med 1993; 34:1927-1930.
35. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well differentiated thyroid cancer - A quantitative radiation dosi-metric approach: Outcome and validation in 85 patients. J Nucl Med 1992; 33:1132-1136.
36. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well differentiated thyroid cancer - A quantitative radiation dosi-metric approach: Outcome and validation in 85 patients. J Nucl Med 1992; 33:1132-1136.
37. Hodgson DC, Brierley JD, Tsang RW, Panzarella T. Prescribing 131-I iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. Radiother Oncol 1998; 47:325-330.